GlassScriptPhysician profile
Karessa A Presnar
NPI 1184131344
$15,023.01
in general payments reported to CMS, 2019-2025
55 companies · $70.22 in 2025
The $70.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,916 · 2022: $6,829 · 2023: $1,175 · 2024: $33.28 · 2025: $70.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.43 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,222.27 | 2021-2023 | |
| Genzyme Corporation | $1,843.35 | 2021-2023 | |
| Biogen, INC. | $1,459.88 | 2021-2023 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $681.11 | 2021-2023 | Ajovy |
| Novartis Pharmaceuticals Corporation | $663.53 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $547.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $543.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $504.97 | 2021-2023 | Ponvory |
| Ucb, INC. | $488.46 | 2021-2023 | Briviact |
| Emd Serono, INC. | $477.44 | 2021-2023 | |
| Kyowa Kirin, INC. | $425.59 | 2021-2022 | |
| Lilly USA, LLC | $404.95 | 2021-2023 | Reyvow, Emgality |
| Acadia Pharmaceuticals INC | $389.32 | 2021-2023 | Nuplazid |
| Amgen INC. | $379.53 | 2021-2022 | |
| Genentech USA, INC. | $358.68 | 2021-2023 | Ocrevus |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karessa Presnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.